Page 27 - 2020_11-Haematologica-web

Editorials
Haemost. 2009;7(7):1155-1162.
15. Arzamendi D, Dandachli F, Théorêt JF, et al. An anti-von Willebrand
factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. Clin Appl Thromb Hemost. 2011;17(6):E70-78.
16. Markus HS, McCollum C, Imray C, et al. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke. 2011;42(8):2149-2153.
17. Knöbl P, Jilma B, Gilbert JC, et al. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion. 2009;49(10):2181-2185.
18. Mayr FB, Knöbl P, Jilma B, et al. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with throm- botic thrombocytopenic purpura ex vivo. Transfusion. 2010;50(5): 1079-1087.
19. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, et al. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105(3):545-552.
20. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, et al. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;106(3):539-547.
21. Cataland SR, Peyvandi F, Mannucci PM, et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87(4):430-432.
22. Sakai K, Someya T, Harada K, Yagi H, Matsui T, Matsumoto M. Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and com- parable to caplacizumab. Haematologica. Haematologica. 2020;105 (11):2631-2638.
23. Matsunaga KI, Kimoto M, Hirao I, et al. High-affinity aptamer genera- tion targeting von Willebrand factor A1-domain by genetic alphabet expansion for systematic evolution of ligands by exponential enrich- ment using two types of libraries composed of five different bases. J Am Chem Soc. 2017;139(1):324-334.
24. Huang RH, Fremont DH, Diener JL, Schaub RG, Sadler JE. A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure. 2009;17(11):1476-1484.
25. Jilma-Stohlawetz P, Knöbl P, Gilbert JC, et al. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost. 2012;108(2):284-290.
26. Joly BS, Vanhoorelbeke K, Veyradier A. Understanding therapeutic tar- gets in thrombotic thrombocytopenic purpura. Intensive Care Med. 2017;43(9):1398-1400.
27. Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2018;3(1):26-37.
28. Kaur H, Bruno JG, Kumar A, Sharma TK. Aptamers in the therapeutics and diagnostics pipelines. Theranostics. 2018;8(15):4016-4032.
haematologica | 2020; 105(11)
2515